Adverse effect of the CCR5 promoter-2459A allele on HIV-1 disease progression

被引:14
作者
Knudsen, TB
Kristiansen, TB
Katzenstein, TL
Eugen-Olsen, J
机构
[1] Univ Copenhagen, Hvidovre Hosp, Clin Res Unit 136, DK-2650 Hvidovre, Denmark
[2] Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark
[3] Univ Copenhagen, Hvidovre Hosp, Dept Infect Dis, Copenhagen, Denmark
关键词
human genetic polymorphism; CCR5; receptor; 59029; A/G; chemokine-receptors; AIDS;
D O I
10.1002/jmv.2054
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
HIV positive individuals heterozygous for a 32 basepair deletion in the CCR5 encoding gene (CCR5 Delta 32) have a reduced number of CCR5 receptors on the cell surface and a slower progression towards AIDS and death. Other human polymorphisms, such as the CCR2 641 and the CCR5 promoter -2459 A/G transition that has been discovered recently, have also been shown to influence HIV progression. Since genetic linkages make these polymorphisms interdependent variables, the aim of the present study was to isolate and evaluate the effect on HIV disease progression for each of these mutations independently. Genotypes were determined in 119 individuals enrolled in the Copenhagen AIDS Cohort. When including the concurrent effects of the CCR5 Delta 32 and CCR2 641 mutations, homozygous carriers of the CCR5 promoter -2459A allele had a significantly faster progression towards death than heterozygous A/G individuals (P = 0.03), whereas this adverse effect was not significant when comparing A/A and G/G individuals. However, independent analysis revealed a significant adverse effect of the CCR5 promoter -2459A allele. Homozygous carriers of the -2459A allele that lack the protective effects of the CCR5 Delta 32 and CCR2 641 mutations were found to have a median survival of 6.0 years, whereas carriers of the -2459G allele had a median survival of 9.4 years (P < 0.01). (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:441 / 444
页数:4
相关论文
共 18 条
[1]   CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors [J].
Clegg, AO ;
Ashton, LJ ;
Biti, RA ;
Badhwar, P ;
Williamson, P ;
Kaldor, JM ;
Stewart, GJ .
AIDS, 2000, 14 (02) :103-108
[2]   Chemokine receptor polymorphisms and human immunodeficiency virus disease progression [J].
Easterbrook, PJ ;
Rostron, T ;
Ives, N ;
Troop, M ;
Gazzard, BG ;
Rowland-Jones, SL .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (04) :1096-1105
[3]   Chemokine receptor CCR2b 64I polymorphism and its relation to CD4 T-cell counts and disease progression in a Danish cohort of HIV-infected individuals [J].
Eugen-Olsen, J ;
Iversen, AKN ;
Benfield, TL ;
Koppelhus, U ;
Garred, P .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 18 (02) :110-116
[4]   Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals [J].
EugenOlsen, J ;
Iversen, AKN ;
Garred, P ;
Koppelhus, U ;
Pedersen, C ;
Benfield, TL ;
Sorensen, AM ;
Katzenstein, T ;
Dickmeiss, E ;
Gerstoft, J ;
Skinhoj, P ;
Svejgaard, A ;
Nielsen, JO ;
Hofmann, B .
AIDS, 1997, 11 (03) :305-310
[5]   Dual effect of CCR5 Delta 32 gene deletion in HIV-1-infected patients [J].
Garred, P ;
EugenOlsen, J ;
Iversen, AKN ;
Benfield, TL ;
Svejgaard, A ;
Hofmann, B ;
Koppelhus, U ;
Pedersen, C ;
Sorensen, AM ;
Katzenstein, T ;
Gerstoft, J ;
Skinhoj, P ;
Nielsen, JO ;
Dickmeiss, E .
LANCET, 1997, 349 (9069) :1884-1884
[6]  
KASTEN S, 2000, EUR J MED RES, V18, P323
[7]  
Kristiansen TB, 1998, SCAND J IMMUNOL, V48, P339, DOI 10.1046/j.1365-3083.1998.00438.x
[8]   Genetic acceleration of AIDS progression by a promoter variant of CCR5 [J].
Martin, MP ;
Dean, M ;
Smith, MW ;
Winkler, C ;
Gerrard, B ;
Michael, NL ;
Lee, B ;
Doms, RW ;
Margolick, J ;
Buchbinder, S ;
Goedert, JJ ;
O'Brien, TR ;
Hilgartner, MW ;
Vlahov, D ;
O'Brien, SJ ;
Carrington, M .
SCIENCE, 1998, 282 (5395) :1907-1911
[9]   CCR5 promoter polymorphism and HIV-1 disease progression [J].
McDermott, DH ;
Zimmerman, PA ;
Guignard, F ;
Kleeberger, CA ;
Leitman, SF ;
Murphy, PM .
LANCET, 1998, 352 (9131) :866-870
[10]   CCR5-Delta 32 gene deletion in HIV-1 infected patients [J].
Michael, NL ;
Louie, LG ;
Sheppard, HW .
LANCET, 1997, 350 (9079) :741-742